Breaking News
April 19, 2018 - Novel biomarker can distinguish malignant lung nodules
April 19, 2018 - Study reports promising novel approach to treat therapy resistant pediatric brain tumors
April 19, 2018 - One-Hour Plasma Glucose Useful Predictor of Diabetic Retinopathy
April 19, 2018 - Hydroxychloroquine no more effective than placebo for relieving osteoarthritis hand pain
April 19, 2018 - Transplanted livers have a protective effect and reduce potential for organ rejection
April 19, 2018 - Researchers develop new method to study activity of inflammatory cells
April 19, 2018 - Researchers discover highly antibiotic resistant superbugs in Gulf States
April 19, 2018 - U.S. Women Less Likely Than Men to Get Statins After Heart Attack
April 19, 2018 - Atypical brain development observed in preschoolers with ADHD symptoms
April 19, 2018 - SC Johnson releases annual Sustainability Report
April 19, 2018 - Positive attitudes about aging reduce risk of dementia in older adults
April 19, 2018 - Environmental pollutants found to worsen rheumatoid arthritis
April 19, 2018 - UT Southwestern scientists discover protein linked to metastatic breast cancer
April 19, 2018 - Study highlights need for further evidence to improve symptom management in end of life care
April 19, 2018 - Detecting diminished dopamine-firing cells inside brain could reveal earliest signs of Alzheimer’s
April 19, 2018 - Uniqsis offers high-power LED light unit for scalable flow photochemistry reactions
April 19, 2018 - Case study shows how intravascular ultrasound imaging helps detect acute aortic syndrome
April 19, 2018 - Research reveals new mechanism by which HIV evades the immune system
April 19, 2018 - Nanodisc-delivered cancer treatment helps eliminate tumors
April 19, 2018 - Functional connectivity MRI could help detect brain disorders and diseases
April 19, 2018 - Finding better way to quantify neuropathy symptoms and treatment efficacy
April 19, 2018 - Study examines effectiveness of caregiver education about sickle cell trait
April 19, 2018 - High-resolution images of tumor vasculature using new technology
April 19, 2018 - Lack of sleep may be linked to risk factor for Alzheimer’s disease
April 19, 2018 - Study finds neurotransmitter may play a role in alcohol relapse, addiction
April 19, 2018 - Researchers build molecular networks of calcific aortic valve disease
April 19, 2018 - Researchers develop highly specific apoptosis assay for pharmacodynamic analyses of tumor specimens
April 19, 2018 - Scientists decipher mechanism of chemotherapy induced female infertility
April 19, 2018 - New insight may allow researchers to design drugs that improve immune responses to vaccines
April 19, 2018 - FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia
April 19, 2018 - Researchers uncover origin of virus-fighting plasma B cells
April 19, 2018 - Study finds no evidence of lower intelligence in young children who had anesthesia
April 19, 2018 - Baboons break out of research facility briefly
April 19, 2018 - Study shows how deployment time increases risk of suicide attempt in soldiers
April 19, 2018 - Specific odors from malaria infected individuals attract more mosquitoes
April 19, 2018 - FDA Alert: Rhino 69 Extreme 50000 by AMA Wholesale: Recall
April 19, 2018 - Top HIV cure research team refutes major recent results on how to identify HIV persistence
April 19, 2018 - Experts propose new solutions to increase benefit, affordability of targeted cancer medicines
April 19, 2018 - Deficiency of innate immune adaptor TRIF shortens survival time of ALS mice
April 19, 2018 - New machine learning method offers better way to detect heart disease
April 19, 2018 - CNIO researchers determine structure of protein complex related to cell survival
April 19, 2018 - Faith-based diabetes support program launched by UTSA research team
April 19, 2018 - Volumetric Laser Endomicroscopy Helps ID Barrett’s Regions
April 19, 2018 - Engineered cartilage template to heal broken bones
April 19, 2018 - New computational framework accurately predicts drug-drug and drug-food interactions
April 18, 2018 - Some human cancers may be result of evolutionary accidents, research finds
April 18, 2018 - Higher levels of education linked to lower dementia risk in older African Americans
April 18, 2018 - Smoking Puts Blacks at Higher Risk for Heart Failure
April 18, 2018 - Physiotherapist contributes to guidelines for knee cartilage treatment
April 18, 2018 - Researchers use ‘top-down proteomics’ strategy to get new insights into cancer
April 18, 2018 - Physician assistants less likely to accurately diagnose early stage skin cancers
April 18, 2018 - New faster, streamlined method for bowel cancer detection and treatment
April 18, 2018 - Researchers identify new Listeria species in Costa Rica
April 18, 2018 - Novel interactive diagram shows many facets of mild traumatic brain injury
April 18, 2018 - Short sleep linked to obesity in children and adolescents
April 18, 2018 - When weight loss helps with sleep
April 18, 2018 - New mathematical model can predict efficiency of microbiome therapies
April 18, 2018 - People with high LDL cholesterol levels likely to get greater benefits from statins
April 18, 2018 - Listening to music enhances effect of anti-hypertensive drugs
April 18, 2018 - New method could help treat severe epilepsy in the future
April 18, 2018 - Study reveals increased risks for Alzheimer’s, suicide among youth in polluted cities
April 18, 2018 - Obese patients more likely to develop rapid and irregular heart rate
April 18, 2018 - Study may change global guidelines for managing children with uncomplicated fever
April 18, 2018 - Researchers find letter we’ve seen millions of times, yet can’t write
April 18, 2018 - Roswell Park researchers identify driver of cancer-promoting metabolic changes
April 18, 2018 - Study shows connection between early life stress, depression and sleep disturbances
April 18, 2018 - New tool developed to protect women from HIV infection
April 18, 2018 - Tradeshow Talks with HealthSapiens
April 18, 2018 - NYC mice carry deadly bacteria and viruses
April 18, 2018 - FDA Approves Tavalisse (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia
April 18, 2018 - Doctors curbing first-time prescriptions for opioids
April 18, 2018 - Scientists analyze nanostructure of chicken eggshells
April 18, 2018 - Study finds muscle complications among active young adults with Type 1 diabetes
April 18, 2018 - Young children should be priority for snail fever treatment
April 18, 2018 - One class of diabetes drug not associated with reduced risk of death
April 18, 2018 - Breakthrough microscope revolutionizes live cell imaging of stem cells
April 18, 2018 - Study on arthritis prevalence and trends reveals unexpected findings
April 18, 2018 - Low-Vision Rehab Improves Several Elements of Visual Function
April 18, 2018 - Babies who look like their father at birth are healthier one year later: study
April 18, 2018 - New drug for migraine in the pipeline
New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too

New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too

image_pdfDownload PDFimage_print

WEDNESDAY, Dec. 6, 2017 — Adding a new drug to standard treatment can slow the progression of advanced breast cancer in younger women, a new clinical trial has found.

The drug, called ribociclib (Kisqali), was approved by the U.S. Food and Drug Administration in March for the treatment of postmenopausal women with advanced breast cancer.

Now, experts say, the drug is just as effective for premenopausal women.

In the trial, the treatment typically doubled the time a woman remained free of cancer progression — from roughly one year to two years.

That benefit is “strikingly similar” to what’s been seen in postmenopausal women, said Dr. Neil Iyengar, who specializes in treating breast cancer at Memorial Sloan Kettering Cancer Center in New York City.

Breast cancer occurs most often in older women, and tumors that develop before menopause tend to be more aggressive, explained Iyengar.

“This is an important study because it addresses the question of whether a treatment is as effective for premenopausal women as it is for postmenopausal women,” he said. Iyengar was not involved in the research.

Kisqali is one of several new drugs called CDK4/6 inhibitors. They work by blocking two proteins that help cancer cells grow and divide.

The drug was specifically approved as a first-line treatment for postmenopausal women with advanced breast cancer that is hormone receptor-positive — which means estrogen fuels the cancer’s growth.

It is meant to be used along with an aromatase inhibitor, a drug that blocks estrogen production in postmenopausal women. Aromatase inhibitors can be given to premenopausal women if they’re used with medication that shuts down the ovaries’ production of estrogen.

The new trial involved 672 women with advanced breast cancer, aged 25 to 58, who were premenopausal or going through menopause.

All of the women were given standard hormonal therapy — an aromatase inhibitor or the drug tamoxifen — plus ovary-suppressing medication. Half were randomly assigned to take Kisqali in addition. The other half took inactive placebo tablets.

The main focus of the trial was “progression-free survival” — how long a patient lives without the cancer getting worse.

Overall, women taking Kisqali were typically progression-free for two years, versus 13 months for women on standard treatment only.

The findings offer “clear proof” that the drug can work just as well for younger women, said the trial’s lead researcher, Dr. Debu Tripathy. He’s a professor of medicine and chairman of the breast medical oncology department at the University of Texas M.D. Anderson Cancer Center, in Houston.

Tripathy cautioned, though, that Kisqali is not yet approved for premenopausal women.

Last month, Kisqali’s maker Novartis said it would “begin discussions” with drug regulators based on these trial results.

Tripathy, who is a paid consultant to Novartis, was scheduled to present the findings Wednesday at the San Antonio Breast Cancer Symposium. Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

Kisqali does have downsides. For instance, it’s known to often cause a drop in certain white blood cells that help fight off infections.

In this study, three-quarters of the women who took Kisqali had a decline in blood cells called neutrophils, though most didn’t have symptoms, according to Tripathy.

A small number of women had what’s called a QT prolongation — a change in the heart’s electrical activity that can trigger an abnormal heart rhythm. Novartis says that as a “precaution,” Kisqali patients should have their heart activity checked before and during treatment.

The study does not answer the question of whether the drug ultimately extends women’s lives, Tripathy said.

But, he added, that’s a tough question, because once a woman’s cancer progresses, she’ll typically try other treatments — like chemotherapy or newer “targeted” drugs.

Iyengar agreed. And, he said, researchers are still trying to figure out the best course of treatment once patients do have a progression.

For now, Iyengar said, “this study gives us new and convincing evidence that a lot of doctors and patients will want to consider.”

Cost, and what insurance will cover, is another issue. Kisqali, like other CDK4/6 inhibitors, costs thousands of dollars for one 28-day cycle of treatment.

More information

The U.S. Centers for Disease Control and Prevention has more on breast cancer in younger women.

© 2017 HealthDay. All rights reserved.

Posted: December 2017

Recommended for you

Tagged with:

About author

Related Articles